ArticleCancer science2022

Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance.

Nobuyuki Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.